This website is intended for healthcare professionals. If you are a member of the public, please  visit our public website.

You've probably never seen an oral iron like Feraccru before

Feraccru is indicated for the treatment of iron deficiency (ID) in adults.1

Understanding iron deficiency

ID is one of the most common and widespread nutritional disorder in the world, and is defined as a condition in which there are no mobilisable iron stores and signs and/or symptoms of a compromised supply of iron to tissues.2 The more severe stages of ID are associated with anaemia, therefore iron deficiency anaemia (IDA)  is regarded as a subset of iron deficiency and is used to screen for ID.2 The terms anaemia, ID, and IDA are sometimes used interchangeably.2 There are, however, mild-to-moderate forms of ID in which, although anaemia is absent, tissues are still functionally impaired.2

ID prevalence in adults is 4-12% dependent on age and sex,2 whereas IDA has a prevalence 2–5% among adult men and postmenopausal women.2

Feraccru is different from other iron treatments

Feraccru contains the ferric form of iron (Fe3+). Most oral iron treatments contain the ferrous form of iron (Fe2+).3-5 Feraccru creates a stable complex for delivery by tightly binding ferric iron to three maltol molecules.1 It’s this unique structure that makes it an efficacious, well‑tolerated oral iron treatment for adult patients with ID.6,7

See how Feraccru is different from other iron treatments and why it matters

Discover Feraccru

What is Feraccru? What is Feraccru?
How does Feraccru work? How does Feraccru work?
Feraccru clinical trial data Feraccru clinical trial data
When to use Feraccru When to use Feraccru
Resources Resources

References

  1. Feraccru. Summary of Product Characteristics. Shield Therapeutics. March 2018. Available at: https://www.medicines.org.uk/emc/medicine/31722. Accessed June 2018.
  2. World Health Organization. Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. 2001.
  3. Goddard AF, et al. Gut 2011;60:1309–1316.
  4. Ferrous Sulphate Tablets BP 200mg. Summary of Product Characteristics. Actavis UK Ltd. December 2016. Available at: https://www.medicines.org.uk/emc/medicine/24195. Accessed June 2018.
  5. Ferrous fumarate 210mg Tablets. Summary of Product Characteristics. Concordia International. April 2016. Available at: http://www.medicines.org.uk/emc/medicine/27076/SPC. Accessed June 2018.
  6. Gasche C, et al. Inflamm Bowel Dis 2015;21(3):579–588.
  7. Schmidt C, et al. Aliment Pharmacol Ther 2016;44(3):259–270.